Ardent Health Lowers FY2026 GAAP EPS Guidance from $0.90-$1.27 to $0.78-$1.15 vs $1.09 Est; Affirms FY2026 Sales Guidance of $6.400B-$6.700B vs $6.441B Est

Benzinga Newsdesk www.benzinga.com Negative 95.8%

Neg 95.8% Neu 0% Pos 0%

Ardent Health (NYSE:ARDT) lowers FY2026 GAAP EPS guidance from $0.90-$1.27 to $0.78-$1.15 vs $1.09 analyst estimate. Affirms FY2026 sales outlook from $6.400 billion-$6.700 billion to $6.400 billion-$6.700 billion vs $6.441 billion estimate.